After months of back and forth between companies and their management teams, on Wednesday (January 24) Aurora Cannabis (TSX:ACB; OTCQB:ACBFF) managed to secure the acquisition of fellow Licensed Producer (LP) CanniMed Therapeutics (TSX:CMED) in a deal worth approximately $1.1 billion.
Both CanniMed’s board of directors and the special committee formed to investigate the Aurora takeover bid and agreed to support the new offer.
Shareholders for CanniMed will be presented with the option to pick between receiving 3.40 Aurora shares or a cash and shares combination. However, Aurora said there is a maximum $140 million cash dedicated to this resolution.
Brent Zettl, president and CEO of CanniMed went to great ordeals to explain why this acquisition attempt from Aurora wasn’t worth it to his shareholders. In the joint statement, he said the transaction confirmed his company had become a global leader in the medical cannabis market.
The dispute between the two TSX listed LPs had become so tense that CanniMed even raised a $725 million lawsuit against Aurora, claiming “wrongdoing” related to CanniMed’s takeover bid.
CanniMed argued for breaches of confidentiality, intentional interference with economic relations, conversion, and breach of contract among other allegations. In their joint statement, there was no mention or update on the development of the lawsuit.
As the Canadian market prepares for an increase in demand for cannabis as recreational legalization nears, Aurora has been on a path of acquisition over the past few months, seeking to increase their production numbers. With this blockbuster purchase, Aurora is looking to increase its scope when it comes to meeting demand both in and outside of Canada.

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

Shares of Newstrike decline after being left out of acquisition deal

With the completion of Aurora’s takeover bid, the deal in place for Newstrike Resources (TSXV:HIP) to be acquired by CanniMed has effectively been canceled. This case proved to be a contentious fight for Aurora, as they made their hostility against this deal clear.
The acquisition of Newstrike was deemed a “poison pill” tactic meant to get rid of Aurora’s takeover attempt for CanniMed.
Newstrike issued a statement announcing the deal, one that their shareholders voted in favor of, which then fell through with CanniMed. According to the release, Newstrike is set to receive a $14.1 million package due to the termination of the planned transaction.
Jay Wilgar, CEO of Newstrike, said the company will use the money to increase the efforts for their Niagara Facility greenhouse to begin producing ahead of schedule and to speed up the roll-out of their lifestyle brand Up Cannabis.
The fallout of this deal particularly affects Newstrike after its shareholders showed a vote of confidence by overwhelmingly approving the CanniMed takeover attempt, as part of a special meeting last week.
Earlier in this week reports indicated Aurora was potentially considering bringing Newstrike along in what would have been one of the largest transactions ever in the cannabis industry. On Tuesday (January 23), shares of or Newstrike rose thanks to the speculation, reaching a week-high price of $2.62.
At market closure on Wednesday, Newstrike faced a 19.23 percent decline to its stock while CanniMed soared, reaching a new year high share $43.18 price per share during trading hours and closing with an 85.81 percent increase over a year-to-date period. Aurora, on the other hand, closed the day with a 5.48 percent decline to its share price.


US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

Investor Takeaway

Despite today’s decline for Newstrike, Aaron Salz a cannabis advisor with the independent group Stoic Advisory, tweeted on Wednesday the TSXV listed company was actually the biggest winner from this entire case.

It will be interesting for investors to follow through the full impact this failed deal will have on Newstrike’s share price moving forward.
Editor’s note: This story was updated to reflect the changes in share price for each company at market closure.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to provide a corporate update on its psychedelic pharmaceuticals program. Since its inception, the Company has built a unique product pipeline for novel uses of ketamine, psilocybin and undisclosed psychedelics. PharmaTher is positioning itself to partner its psilocybin program and panaceAI™, and focus on advancing its novel ketamine product pipeline in Parkinson’s disease, depression and pain via the U.S. Food and Drug Administration (“FDA”) regulatory pathway.

“We have made tremendous progress over the last several months that saw our product pipeline evolve to focus on the massive opportunity and potential of ketamine, an FDA approved drug with a known safety profile, to treat significant unmet medical needs for Parkinson’s disease, depression and pain,” said Fabio Chianelli, CEO of PharmaTher. “With our focus on ketamine through repurposing, combining it with an FDA approved drug and delivering it with our novel microneedle delivery system, we are now positioned to expedite our clinical development objectives by taking advantage of the FDA’s 505(b)(2) regulatory pathway and commercializing disruptive ketamine treatments for mental health and pain disorders.”

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN), Aurora Cannabis (NYSE: ACB)(TSX: ACB), and Canopy Growth Corporation (NASDAQ: CGC) (TSX: WEED).

Cannabis leaders are focusing on innovation in premium branding, global expansion, and tight operational execution in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders:

Keep reading... Show less

Chemesis International Inc. (the “Company”) (CSE:CSI)(OTCQB:CADMF)(FRA:CWAA

The Company announces that its (former) subsidiary, Natural Ventures PR, LLC (“NVPR”), has sold all of its cannabis assets, and assigned all related liabilities, licenses and permits, to Puerto Rico Industrial Commercial Holdings Biotech Corp. (“PRICH”) in exchange for immediate net cash proceeds to the Company, in respect of its 80% interest in NVRP, of US$450,000. The Company notes that, in connection with, and as a condition to, this transaction, it will cease to be a shareholder of NVPR.

Keep reading... Show less

Progressive Planet Solutions Inc. (TSXV: PLAN) (“PLAN” or “Progressive Planet”), an emerging leader in reducing the carbon footprint of cement products using natural pozzolans, is pleased to announce it has sold and optioned a combined total of 10 million of its 10.5 million shares of Snow Lake Resources.

The sale and option agreements were made with two arms-length purchasers. The first sale was for 1,700,000 shares at $0.04 per share for a total of $68,000 and includes an option granted by PLAN entitling the same party to purchase an additional 4,966,666 shares at $0.04 per share until May 11, 2021 . The second sale was for 1,250,000 shares at $0.04 per share for a total of $50,000 and includes an option granted by PLAN to such party to purchase an additional 2,083,334 shares until August 14, 2021 . As at the date of this news release, PLAN has received $116,000 and will receive another $284,000 if the remaining shares are purchased under the option agreements.

Keep reading... Show less

First Products to Hit California Shelves in Q2 2021

 4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that its fully funded state of the art 185,000 square foot production facility in Commerce, California is nearing completion and will be ready to serve the $3b California cannabis market in Q2 2021. The project is on target to be completed in April 2021 with the Company planning for the first of its full line of edibles, tinctures and vape products to be on California retail shelves by May.

Keep reading... Show less